Advertisement
Article Free access | 10.1172/JCI12902
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Leitges, M. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Mayr, M. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Braun, U. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Mayr, U. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Li, C. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Pfister, G. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Ghaffari-Tabrizi, N. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Baier, G. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Hu, Y. in: JCI | PubMed | Google Scholar
1Max Planck Institute for Experimental Endocrinology, Hannover, Germany2Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria3Institute for Pathophysiology, and4Institute for Medical Biology and Human Genetics, University of Innsbruck Medical School, Innsbruck, Austria5Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom
Address correspondence to: Qingbo Xu, Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrance, London SW17 0RE, United Kingdom. Phone: 44-20-8725-2817; Fax: 44-20-8725-2812; E-mail: q.xu@sghms.ac.uk.
Find articles by Xu, Q. in: JCI | PubMed | Google Scholar
Published November 15, 2001 - More info
Smooth muscle cell (SMC) accumulation is a key event in the development of atherosclerosis, including vein bypass graft arteriosclerosis. Because members of the protein kinase C (PKC) family signal cells to undergo proliferation, differentiation, or apoptosis, we generated PKCδ knockout mice and performed vein bypass grafts on these animals. PKCδ–/– mice developed normally and were fertile. Vein segments from PKCδ–/– mice isografted to carotid arteries of recipient mice of either genotype led to a more severe arteriosclerosis than was seen with PKCδ+/+ vein grafts. Arteriosclerotic lesions in PKCδ–/– mice showed a significantly higher number of SMCs than were found in wild-type animals; this was correlated with decreased SMC death in lesions of PKCδ–/– mice. SMCs derived from PKCδ–/– aortae were resistant to cell death induced by any of several stimuli, but they were similar to wild-type SMCs with respect to mitogen-stimulated cell proliferation in vitro. Furthermore, pro-apoptotic treatments led to diminished caspase-3 activation, poly(ADP-ribose) polymerase cleavage, and cytochrome c release in PKCδ–/– relative to wild-type SMCs, suggesting that their apoptotic resistance involves the loss of free radical generation and mitochondrial dysfunction in response to stress stimuli. Our data indicate that PKCδ maintains SMC homeostasis and that its function in the vessel wall per se is crucial in the development of vein graft arteriosclerosis.
Protein kinase C (PKC) isoforms play an important role in intracellular signaling and are divided into three subfamilies based on differences in the regulatory domain and the substrates required (1). Since the isoforms are expressed on different genes, they have a strictly regulated tissue expression, display biochemical diversities, and seem to have distinct biological functions (2, 3). For example, PKCδ, a major isozyme ubiquitously expressed in most mammalian cells, was reported to inhibit growth, induce differentiation, and promote apoptosis in vascular smooth muscle cells (SMCs) and other types of cells (4–7), while PKCθ was reported to be crucial in mediating NF-κB activation in mature T cells (8). However, most of our knowledge concerning the regulation and function of PKC isozymes has come from studies of cultured cells using PKC inhibitors, and little is known about their specific role in the development of vascular diseases.
Autologous vein grafts remain the only surgical alternative for many types of vascular reconstruction, but obliterative arteriosclerosis often follows. The pathogenesis of this disease is poorly understood, and no successful clinical interventions have been identified (9). It has been demonstrated that SMC proliferation/accumulation in the intima of the vessel wall is a key event in the development of arteriosclerosis (10, 11). Abundant evidence also indicates the importance of SMC apoptosis in the pathogenesis of the disease (12, 13). Since SMC proliferation and apoptosis coincide in arteriosclerotic lesions, the balance between these two processes could be a determinant during vessel remodeling and disease development. Accumulating evidence indicates the importance of PKC family members in cell proliferation and apoptosis (4–7, 14). To elucidate the role of PKCδ in the pathogenesis of arteriosclerosis, we have generated a knockout mouse that lacks PKCδ expression in a broad range of organs. We demonstrate that PKCδ–/– mice had markedly increased arteriosclerotic lesions in their vein grafts compared with wild-type mice.
Generation of PKCδ mutant mice. We have inserted a LacZ/neo cassette into the first transcribed exon of the gene (Figure 1a) using the standard techniques of the gene targeting approach (15). As a consequence of the insertion, the transcription is abolished and leads to a null allele. For genotyping adult mice with a background of 129/SV×Ola, a Southern blot analysis of EcoRI digested genomic DNA was performed. DNA was extracted from adult tail tissue and hybridized with an endogenous 5′-probe (Figure 1b) distinguishing wild-type, heterozygote mutant, and homozygote mutant alleles. The 5′-probe corresponded to a 0.8-kb HindIII/BamHI fragment hybridizing to a 10.0-kb band in the wild-type and a 7.0-kb band in the successfully mutated allele.
Targeted mutation of the PKCδ locus in mice (a) Restriction map of the PKCδ locus (wt). The targeting vector was integrated into the endogenous locus by homologous recombination and gave rise to the mutant PKCδ LacZ locus. B, BamHI; E, EcoRI; H, HindIII; F, FspI. (b) Southern blot analysis of a litter derived from a heterozygote intercross. Genomic EcoRI fragments detected with a 5′-probe indicating wild-type (wt) and mutant (mt) alleles. The homozygote animal is represented in lane 1; heterozygote animals are represented in lanes 2 and 4; lane 3 is representative for wild-type animals. (c) Western blot analysis of protein extracts from homozygote and wild-type mice showing undetectable PKCδ proteins of tissues from PKCδ knockout mice.
Vein graft procedure. The vein grafts were performed using homozygous PKC-null and wild-type littermates of the heterozygous cross as donors and recipients. The procedure used for vein grafts was similar to that described previously (16). Briefly, the vena cava vein (about 1 cm) was harvested, the right common carotid artery was mobilized, and a cuff was placed at the end. The artery was turned inside out over the cuff and ligated. The vein segment was grafted between the two ends of the carotid artery. Vein grafts were harvested at 8 weeks postoperatively by cutting the implanted segments from native vessels at the cuff end (12 mice per group).
Histology and lesion quantification. For histological analysis, in vivo perfusion with 4% phosphate-buffered formaldehyde was performed, as described previously (16, 17). Vein grafts were harvested by cutting the implanted segments from the native vessels at the cuff end. The grafts were dehydrated in graded ethanol baths, cleared in xylol, embedded in paraffin, and sectioned. In our mouse model we have proved anastomosis using a cuff technique that results in less damage to the graft. To avoid anastomotic effects, sections from the midportion of the graft (two-thirds of length) were collected. Since there is only one layer or two layers of cells in the media of mouse veins and no morphological border between neointima and media, neointima lesions were defined as the region between the lumen and adventitia that contains capillary blood vessels. For lesional area measurement, sections were reviewed using a BX60 microscope (Olympus Optical Co., Tokyo, Japan) equipped with a Sony 3CCD camera (Sony Ltd., Osaka, Japan) and television monitor (17). The lesion was defined as the region between the lumen and the adventitia. Using a transmission scanning microscope (Zeiss LSM 510; Zeiss GmbH, Jena, Germany), equipped with a 488-nm argon ion laser and Plan Neofluar 10×/0.3 oculars (Zeiss GmbH), images were first scanned and saved and then overlaid by different linings to trace the lumen and adventitia. The lesion area was determined by subtracting the area of the lumen from the area enclosed by the line inside of the adventitia.
Immunofluorescent staining. The procedure used for immunofluorescent staining was similar to that described previously (18). Briefly, serial 5-μm-thick frozen sections were labeled with a rat monoclonal antibody against mouse MAC-1 (CD11b/18) leukocytes (PharMingen Biotech Inc., San Diego, California, USA)a mouse monoclonal antibody against α-actin conjugated with Cy3 (Sigma-Aldrich Co., Dorset, United Kingdom), or rabbit anti–proliferating cell nuclear antigen (anti-PCNA) antibodies (DAKO Ltd., Copenhagen, Denmark).
TUNEL assay. Accumulated internucleosomal DNA fragments were detected using an in situ apoptosis detection kit (Boehringer Mannheim Corp., Mannheim, Germany) as described previously (19). Sections were labeled with anti–α-actin-Cy3 (Sigma Chemical Co., St. Louis, Missouri, USA) and examined by confocal microscopy. The percentage of positively stained cells was determined by counting the numbers of labeled and total cells. Positive cells from two regions of each section of 8-week grafts were counted.
SMC proliferation and viability assays. Vascular SMCs from PKCδ–/– and PKCδ+/+ mice were cultivated from their aortae, as described elsewhere (20). Cells were incubated at 37°C for 7–10 days and passaged by treatment with 0.05% trypsin/0.02% EDTA solution. The purity of SMCs was routinely confirmed by immunostaining with antibodies against α-actin. Experiments were conducted on SMCs that had just achieved confluence. For proliferation assays, SMCs (2 × 103) cultured in 96-well plates in medium containing 10% FCS at 37°C for 24 hours were serum-starved for 2 days. Angiotensin II, endothelin-1, and FCS were added, and incubated at 37°C for 24 hours. For the cell viability assay, SMCs were plated at a density of 2 × 103 cells per well (96-well plate) in medium containing 10% FCS and incubated at 37°C for 48 hours. H2O2 was added to the culture, and incubated at 37°C for 24 hours or as indicated. A proliferation/apoptosis kit (Promega Corp., Madison, Wisconsin, USA) was used, and the optical density at 490 nm was recorded by photometry.
Western blot analysis. Cells were washed twice with chilled (4°C) PBS and harvested on ice in buffer A (21). Fifty to 100 μg of total SMC proteins were separated by electrophoresis on a 7–15% SDS-polyacrylamide gel. The membranes were processed with antibodies to PKCδ (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), cytochrome c, caspase-3, or poly(ADP-ribose) polymerase (PARP; PharMingen). Specific antibody-antigen complexes were detected using an enhanced chemiluminescent detection kit (Amersham Co., Little Chalfont, United Kingdom).
Annexin V/propidium iodide (V/PI)double staining and FACS analysis. Annexin staining was performed according to the manufacturer’s instructions (PharMingen) and as described previously (19). Cellular fluorescence was recorded on the FL1 and FL2 channels of a FACScan flow cytometer (Program Cell Quest; Becton Dickinson Co., Mountain View, California, USA) and expressed on a logarithmic scale. After appropriate markings for negative and positive populations, the percentage of annexin V+/PI– or annexin V+/PI+ cells was determined and compared with untreated controls.
JC-1 labeling. After treatment, SMCs were incubated with JC-1 (Molecular Probes Inc., Eugene, Oregon, USA) as described elsewhere (22). Labeled cells were analyzed by FACS or confocal microscopy.
Detection of reactive oxygen species in cultured SMCs. The oxidative fluorescent dyes dihydroethidine and dihydrorhodamine 123 were used to evaluate in situ production of reactive oxygen species by use of a method described by Miller et al. (23). Both dyes are freely permeable to cells and, in the presence of reactive oxygen species, are oxidized to ethidium and hydrorhodamine, respectively. Ethidium is trapped by intercalating with the DNA with an emission spectrum of 610 nm (red), while hydrorhodamine 123 labels proteins in cytoplasm with green fluorescence.
To assess reactive oxygen species production within SMCs, we used a quantitative measure, the oxidation of dihydrorhodamine 123 and dihydroethidium (24). SMCs cultivated on a chamber slide were treated with ultraviolet (UV) light (10 J/m2) as described elsewhere (25) or TNF-α (50 ng/ml) for 5 hours, and then medium was changed. Dihydroethidium and dihydrorhodamine (5 μmol/l) in fresh medium were added and incubated at 37°C for 1 hour. After treatments, supernatants were removed, and cells were washed with PBS and analyzed for rhodamine (green fluorescence) and ethidium (red) oxidation by confocal microscopy. The fluorescence intensity was expressed as optical units.
O2– was quantified spectrophotometrically by monitoring of superoxide dismutase–inhibitable cyto-chrome c reduction according to Zhou et al. (26). Briefly, SMCs were treated with TNF-α (50 ng/ml) for 6 hours and harvested for protein extractions. Fifty microliters of 40 μmol/l cytochrome c (Sigma-Aldrich Co.) and 500 μl of sample were mixed immediately. In controls, 150 μl of 20 μg/ml superoxide dismutase (Sigma-Aldrich Co.) was added. The mixture was incubated for 10 minutes at room temperature, and the absorbance was measured at 550 nm. Reduced cytochrome c was calculated, and the results were expressed as nanomoles per milligram protein.
Statistical analysis. Statistical analyses were performed on a Macintosh computer using the ANOVA and Mann-Whitney U test.
Vein graft arteriosclerosis in PKCδ–/– mice. To determine whether the insertion of the targeting vector into the PKCδ locus leads to a null mutation, we performed Western blot analyses for PKCδ expression using several tissue protein extracts from PKCδ–/– and wild-type mice. As expected, no PKCδ expression was detectable in PKCδ–/– mice (Figure 1c), which confirmed a null allele in the mouse. PKCδ–/– mice were indistinguishable from their wild-type littermates; they developed normally and were fertile.
Recently, we established new mouse models of vein bypass graft arteriosclerosis (16, 17), which have been proven to be useful for studying the pathogenesis of the disease (11). The venous wall of the mouse is composed of intima, a monolayer of endothelium, media, one or two layered SMCs, and adventitia, a small amount of connective tissues (16). In the present experiment, a vena cava segment was isografted into the carotid artery in PKCδ–/– or wild-type mice. Vein grafts of wild-type mice at 8 weeks (Figure 2a) showed neointimal hyperplasia, i.e., thickening of the vessel wall by up to 20 layers of cells, whereas normal veins have only two to three layers of cells. Interestingly, intimal lesions of vein grafts in PKCδ–/– mice showed a marked increase 8 weeks after grafting (Figure 2b). The lumen of vein grafts in 4 of 12 PKCδ–/– mice was completely occluded (Figure 2c). Figure 2d summarizes statistical data of lesion thickness and areas measured with a laser microscope by transmission scanning. A significant difference between groups of PKCδ–/– and wild-type mice was found at 8 weeks (P < 0.01). In addition, we generated PKCα-deficient mice and, in a parallel experiment, found no significant difference in vein graft lesions between PKCα-deficient and wild-type mice (data not shown).
Hematoxylin and eosin–stained (HE-stained) sections of mouse vein grafts. Under anesthesia, vena cava veins of PKCδ+/+ (a and e) or PKCδ–/– (b, c, and f) mice were removed from the donor and isografted into carotid arteries of the recipient. Animals were sacrificed 8 weeks after surgery, and the grafted tissue fragments were fixed in 4% phosphate-buffered (pH 7.2) formaldehyde, embedded in paraffin, sectioned, and stained with HE. Arrows indicate neointima. (d) Statistical data of neointimal area measured as described in Methods. Data are means ± SEM. *Significant difference between PKCδ–/– and PKCδ+/+ groups, P < 0.01.
Because infiltrating mononuclear cells and other host cells like endothelium and adventitial fibroblasts may exert their role in the development of vein graft arteriosclerosis, vein isografts between PKCδ–/– and PKCδ+/+ mice were performed. Figure 3 shows data indicating that vein segments donated by PKCδ–/– mice developed severe arteriosclerosis independent of hosts or recipients. However, PKCδ+/+ veins grafted into PKCδ–/– mice showed that neointimal lesions were not significantly different from those in veins grafted among PKCδ+/+ mice (Figure 3). These results suggest that PKCδ in cells of the grafted vessel wall per se is responsible for the enhanced lesion development.
Lesions in vein isografts between PKCδ–/– and PKCδ+/+ mice. Vein grafts were performed as described in the legend to Figure 2 and in Methods. Data are means ± SEM of six animals per group. *Significant difference from PKCδ+/+ veins grafted to PKCδ+/+ or PKCδ–/– mice, P < 0.05.
Neointimal hyperplasia in both vein grafts was characterized by mononuclear cell infiltration, SMC accumulation, and matrix protein deposition. Double immunofluorescence staining demonstrated the presence of MAC-1–positive monocytes/macrophages (green) and α-actin–positive SMCs (red) in neointimal lesions from PKCδ+/+ (Figure 4a) and PKCδ–/– (Figure 4b) vein grafts. However, total numbers of SMCs in lesions of PKCδ–/– mice were significantly higher than in those of PKCδ+/+ mice (Figure 4c). Because of the rapid development of arteriosclerotic lesions and increased SMC accumulation in PKCδ–/– mice, we chose to investigate the cell turnover in vein grafts. PCNA was used as a cell-replicating marker for labeling of vein grafts from both groups. Summarized data in Figure 4d show a similarity in the percentage of PCNA+ cells in neointima lesions of PKCδ–/– and PKCδ+/+ mice. We also performed TUNEL assays to determine cell death in vein grafts. Figure 4, f–h, shows typical examples of TUNEL+ (green) SMCs (red) in neointima lesions of both vein grafts. Quantitative analysis revealed that apoptotic/necrotic cells in lesions of PKCδ–/– mice were markedly lower than those in neointima from wild-types (Figure 4e; P < 0.05). Therefore, decreased SMC death may be responsible for exacerbated lesion development in PKCδ–/– mice.
Immunofluorescence double labeling of vein graft sections (a and b). Cryostat sections from mouse vein grafts 8 weeks after surgery were fixed with cold 5% acetone/methanol for 30 minutes, air-dried, and incubated with a rat monoclonal antibody to mouse MAC-1, and then visualized by anti-rat Ig-FITC-conjugated rabbit Ig. After washing, sections were incubated with mouse monoclonal antibody against α-actin conjugated with Cy3 for 30 minutes at room temperature. The sections were examined by laser confocal microscopy. (c and d) Statistical data are means ± SEM of percentage of positive cells. Sections were labeled with α-actin antibody/Cy3 or rabbit anti-PCNA antibodies. Nuclei were stained with Hoechst 33258 (1 μg/ml). Positive cells and total nuclei were counted by microscopy. (e–h) TUNEL staining of vein grafts of PKCδ+/+ (e–g) and PKCδ–/– (e and h) mice. Vein grafts were harvested 8 weeks after surgery, and frozen sections were prepared and stained with TUNEL as described in Methods. Arrows indicate typical examples of TUNEL+ cells in lesions. (e) Statistical data are means ± SEM of three independent experiments, *P < 0.05.
PKCδ–/– SMCs are resistant to death in vitro. Because of decreased cell death in PKCδ–/– grafts, we compared the proliferative ability and viability of cultivated arterial SMCs from PKCδ–/– and PKCδ+/+ mice. In response to serum, angiotensin II, and endothelin-1, SMCs from both types of mice replicated markedly, but no significant differences in cell numbers were observed (data not shown). On the other hand, PKCδ-deficient SMCs had a lower level of cell death stimulated by H2O2 (Figure 5). The survival of wild-type SMCs from mice was decreased in a time- and concentration-dependent manner, while PKCδ–/– SMCs showed a resistance to H2O2-induced cell death (Figure 5).
SMC viability in response to H2O2. Vascular SMCs from PKCδ–/– and PKCδ+/+ mice were cultivated from their aortae. SMCs were plated at a density of 2 × 103 cells per well (96-well plate) in medium containing 10% FCS and incubated at 37°C for 48 hours. H2O2 (a; 50 μM) was added to the culture, and incubated at 37°C for the indicated times (a) or 24 hours (b). Solutions from a proliferation/survival kit were added and incubated for 2 hours. The optical density at 490 nm was recorded by photometry. Data are means of three separate experiments.
There is evidence that a large number of macrophages and T lymphocytes are present in the lesions of vein graft arteriosclerosis (16, 17). These cells may release cytokines like TNF-α or INF-γ, which could play a role in the development of the disease. Treatment with UV irradiation serves as a positive control for studying apoptosis. To further establish cell viability and clarify whether dead cells are apoptotic or necrotic PKCδ–/– and PKCδ+/+ SMCs were treated with UV, TNF-α, IL-1β, IFN-γ, and H2O2 and analyzed with FACS. While annexin V (green) labels apoptotic cells at the early stage, propidium iodide (red) stain cells underwent apoptosis and necrosis (19). Data of double-stained SMCs shown in Figure 6a indicate that the main population of dying SMCs underwent apoptosis. PKCδ-deficient SMCs had a lower rate of both apoptosis and necrosis. To further scrutinize the mechanisms of PKCδ–/– SMC resistance to apoptosis by a variety of stimuli, we undertook Western blot analysis using several antibodies. No PKCδ protein in PKCδ–/– SMCs was detected (Figure 6b). Although no difference in the total amount of cytochrome c proteins derived from whole cell protein extracts was found, the level of cytochrome c in cytosol of PKCδ–/– SMCs was much lower than in PKCδ+/+ SMCs in response to TNF-α stimulation, indicating less cytochrome c release from mitochondria to cytosol (Figure 6b). Proteolytic activation of caspase-3 was detected in PKCδ+/+ SMCs stimulated by H2O2, UV, and cytokines, but not in PKCδ–/– cells. Likewise, PARP proteolytic cleavage was seen in PKCδ+/+ SMCs, while PKCδ–/– cells showed a reduced level of PARP fragmentation (Figure 6b). The same blot probed with the cytochrome c antibody indicates an equal loading of proteins (Figure 6b, lower panel).
Decreased apoptosis of PKCδ–/– SMCs (a). SMCs were treated with UV (10 J/m2) and incubated for 7 hours; with TNF-α and IL-1β (50 ng/ml of each) for 36 hours; or with IL-1β and IFN-γ (50 ng/ml) or H2O2 (100 μm) for 36 hours. Then they were harvested and stained with annexin V–FITC and propidium iodide. Each panel represents an example of three independent experiments, and data on squares are means ± SD, *P < 0.05. (b) Western blot analysis. SMCs were treated with UV (10 J/m2), TNF-α (50 ng/ml), or H2O2 (100 μm) for 20 hours. Mitochondrial and cytosolic proteins were separately extracted and used for determining cytochrome c release (middle panel). Protein extracts from whole SMCs were used for analysis of PKCδ, cleaved caspase-3, PARP, and cytochrome c (lower panel). Data represent results of three similar experiments. Ctl, control. (c) SMCs were exposed to UV (10 J/m2) incubated for 7 hours or cytokines for 36 hours and analyzed with FACS after staining with JC-1. Red color represents mitochondria with high Δψ green color indicates low Δψ, and yellow is an intermediate phase. Note that both cell types coexist, but they differ in distribution.
The detection of mitochondrial depolarization occurring in apoptosis is achieved using JC-1, a cationic dye that exhibits potential-dependent accumulation in mitochondria. Mitochondrial depolarization occurring in the early stages of apoptosis is indicated by a decrease in the red/green fluorescence intensity ratio. A fluorescence emission shift from red to green in JC-1–labeled SMCs was observed. Measurement of mitochondrial potential (ΔΨ) by JC-1 reveals two subpopulations of cells: cells with high and low ΔΨ as indicated by a red and green fluorescence signal, respectively. The extent of complete mitochondrial depolarization (lower right quadrant) was comparable to the rate of apoptosis in Figure 6c after cytokine treatment (0.6% versus 11.6% in PKCδ+/+ SMCs, 0.1 versus 1.6% in PKCδ–/– SMCs). In the intermediate stage, mitochondrial depolarization is indicated by simultaneous red and green fluorescence staining resulting in a yellowish color. This stage is still reversible and does not mean that cells are committed to apoptosis. Minor changes in PKCδ–/– SMCs were induced by UV and TNF-α plus IL-1β (Figure 6c). Observations by confocal microscopy confirmed mitochondrial dysfunction in PKCδ+/+ SMCs (Figure 7c; green) and, to a lesser degree, in PKCδ–/– SMCs (Figure 7d); no changes were seen in untreated SMCs (Figure 7, a and b; red).
(a–d) Confocal microscopic images of SMCs labeled with JC-1. PKCδ+/+ (a and c) and PKCδ–/– (b and d) SMCs were treated with TNF-α (c and d; 50 ng/ml) for 24 hours and labeled with JC-1. Note typical mitochondrial dysfunction seen in PKCδ+/+ SMCs (c; green). (e–j) Determination of in situ free radical generation. PKCδ+/+ (e and g) and PKCδ–/– (f and h) SMCs were stimulated with TNF-α (50 ng/ml) for 5 hours and then with dihydroethidium and dihydrorhodamine 123 (5 μmol/l) for 1 hour. After washing, cells were observed by confocal microscopy. Panels i and j summarize quantitative data of means ± SD of two experiments, *P < 0.001. (k) Graph shows superoxide dismutase–inhibitable (SOD-inhibitable) cytochrome c reduction. *P < 0.05 vs. other groups. Ctl, untreated controls.
There is evidence that PKCδ translocates to cell membranes and mitochondria (7, 27) where it may phosphorylate and activate NADPH oxidases (28). We also observed that PKCδ translocated to SMC membrane and mitochondria in response to UV stimulation (data not shown). To test the role of PKCδ in reactive oxygen species induction, PKCδ–/– and PKCδ+/+ SMCs were stimulated by UV and TNF-α for 5 hours, and then incubated with dihydrorhodamine 123 and dihydroethidium. Results shown in Figure 7 indicate that TNF-α and UV stimulated reactive oxygen species production in PKCδ+/+ SMCs (Figure 7, e and g), but very low levels in PKCδ–/– SMCs (Figure 7, f and h). To semiquantitatively measure the oxidation of fluorescence dyes, we demonstrated that PKCδ–/– SMCs produced significantly lower levels of reactive oxygen species compared with wild-type cells (Figure 7, i and j). To determine whether superoxide production in PKCδ–/– SMCs is altered in response to stimulus, PKCδ–/– and PKCδ+/+ SMCs were treated with TNF-α and cytochrome c reduction was measured. Data shown in Figure 7k indicate that superoxide production in PKCδ–/– SMCs is decreased.
Recent studies demonstrated that one of the most important events during neointima formation in vein grafts is cell death (19), which may evoke an inflammatory response (18) followed by SMC proliferation (20). In the present investigation, we provide what is to our knowledge the first evidence that alterations in SMC death markedly influence the lesion formation of vein grafts, in which PKCδ is a crucial signal transducer mediating SMC apoptosis in vivo and in vitro. These observations could be important for understanding the molecular mechanisms of signal transduction pathways between stress stimuli and cell death in the development of arteriosclerosis.
The past several years have seen a dramatic increase in the number of studies of cell apoptosis in the vasculature during the response to various stressors or risk factors for arteriosclerosis (29–35). These studies provide new insights into understanding the mechanisms of the pathogenesis of, and into prevention and treatment of cardiovascular diseases. For example, p53 gene transfer to the vessel wall leads to increased SMC apoptosis, resulting in decreased neointimal lesions induced by angioplasty (36). Our data provide solid evidence that PKCδ is crucial in mediating SMC apoptosis that influences lesion development in vein grafts. These findings raise the question of whether PKCδ could be a therapeutic target for vascular diseases. If a PKCδ activator or a gene expressing activated PKCδ protein is administered into the vessel wall, reduced arteriosclerotic lesions might be seen in vein grafts or in arteries after angioplasty.
Because native or spontaneous atherosclerosis development in normocholesterolemic mice is rare (37), lesions in native arteries are not found in PKCδ-deficient mice, indicating normal development in physiological situations. On the other hand, in pathological conditions, i.e., vein bypass graft arteriosclerosis, many stressful factors exert their role in the development of the disease. If PKCδ-deficient mice could be crossed with apoE-deficient animals to generate hyperlipidemic models, we may expect that atherosclerotic lesions in double knockout mice develop much more quickly than apoE deficiency alone. Therefore, decreased apoptosis of SMCs in PKCδ-deficient mice may be only seen in the pathological conditions, but not in physiological situations.
Accumulating evidence indicates that PKCδ is emerging as a common intermediate in the apoptotic pathway induced by chemicals and irradiation (38). Inhibition of PKCδ with rottlerin or by expression of a dominant negative PKCδ suppresses caspase activation, DNA fragmentation, and apoptosis in salivary gland epithelial cells and prostate cancer cells, respectively (39, 40). Although the mechanism by which PKCδ exerts its role in apoptosis is not fully elucidated, one possibility is provided by our data that the NADPH oxidase, known as a target for PKC enzymes, showed clearly functional defects on the PKCδ-deficient background, indicating a link between PKCδ function and oxidase action. These data are supported by the fact that PKCδ becomes translocated to cell membranes and mitochondria in response to agonists (7). It was also shown that p47phox and p22phox, two subunits of the NADPH oxidase, can serve as substrates for PKC, i.e., PKC can phosphorylate burst oxidase subunit p47phox and p22phox (28). We have also demonstrated that PKCδ translocated to cell membrane as well as mitochondria in response to agonists (data not shown). Since the majority of cellular oxidases are located in the membrane and mitochondria, PKCδ translocation to these organelles may provide an opportunity to directly interact with oxidases. Thus, our observations provide solid support for the role of PKCδ-mediated cell apoptosis possibly by influence of free radical generation.
We have shown previously that PKC depletion or inhibition by PKC-specific inhibitors in SMCs decreased p38 mitogen-activated protein kinase (p38MAPK) activity in response to mechanical stress, suggesting PKC-dependent p38MAPK activation (41). We have also observed that p38MAPK plays a significant role in mediating SMC apoptosis (19). In the present studies, we demonstrate that PKCδ is important in mediating SMC apoptosis, in which PKCδ might activate p38MAPK signal pathways. Supporting this notion is the fact that p38MAPK activities in PKCδ-deficient SMCs are significantly decreased in response to mechanical stress (C. Li , et al., unpublished observations). Considering all these results together, we hypothesize that PKCδ is involved in both signal pathways, i.e., p38MAPK and oxidases, which could indirectly or directly correlate to free radical generation.
In summary, our results suggest that SMC apoptosis is a crucial event in neointima lesion formation, in which PKCδ plays a pivotal role in signal transduction leading to apoptosis in response to stress stimuli. Because vascular cell apoptosis and proliferation coincide in the development of arteriosclerotic lesions, the balance between these two processes, i.e., proliferation and apoptosis, is a determinant during vessel remodeling or lesion development. If the balance can be modified arbitrarily, e.g., by inhibiting or enhancing PKCδ activities at different stages after vessel grafting, new strategies for prevention and treatment of vein graft disease may be achieved.
This work was supported by grants from the Austrian Science Fund (P13099-BIO to Q. Xu, P14394-BIO to G. Baier); the Austrian National Bank (P7919 to Q. Xu); the Deutsche Forschungsgemeinschaft (Germany; Sta314/2-1 and KE246/7-2 to M. Leitges); and the Oak Foundation (United Kingdom; to Q. Xu). We are grateful to G. Wick for his continuous support. We thank A. Jenewein and F. Davison for excellent technical assistance.